| Synonym |
| Thai / English name |
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : 8 mgResult : NegativeRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : ใบActivity : CYP3A4 INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)Duration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : 8 mgResult : NegativeRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : otherType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 25 microgram/mlDuration : 5 minutesType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Details of the standardized Ginkgo extracts: 4.78% Quercetin, 3.73% Kaempferol, 2.13% Isorhamnetin, 12.0% Quercetin glycoside, 9.65% Kaempferol glycoside, 5.19% Isorhamnetin glycoside, 1.61% Bilobalide, 1.41% Ginkgolide A, 0.31% Ginkgolide J, 5.57% Ginkgolide B, 0.38% Ginkgolide C. - Results: The degree of CYP3A4 inhibition of Ginkgo biloba was 45.9% and IC50 values of that inhibit CYP3A4-mediated metabolism of midazolam = 75.1 microgram/ml, 95% Cl: 53.0-106.Note : The effects of complementary and alternative medicine (CAM) on CYP3A4-mediated metabolism of midazolam and docetaxel were determined in human liver microsomes (HLM), using liquid-chromatography coupled to tandem mass spectrometry (LC-MS/MS).
Part Used : ใบActivity : CYP3A4 INHIBITIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : otherType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 25 microgram/mlDuration : 5 minutesType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Details of the standardized Ginkgo extracts: 4.78% Quercetin, 3.73% Kaempferol, 2.13% Isorhamnetin, 12.0% Quercetin glycoside, 9.65% Kaempferol glycoside, 5.19% Isorhamnetin glycoside, 1.61% Bilobalide, 1.41% Ginkgolide A, 0.31% Ginkgolide J, 5.57% Ginkgolide B, 0.38% Ginkgolide C. - Results: The degree of CYP3A4 inhibition of Ginkgo biloba was 45.9% and IC50 values of that inhibit CYP3A4-mediated metabolism of midazolam = 75.1 microgram/ml, 95% Cl: 53.0-106.Note : The effects of complementary and alternative medicine (CAM) on CYP3A4-mediated metabolism of midazolam and docetaxel were determined in human liver microsomes (HLM), using liquid-chromatography coupled to tandem mass spectrometry (LC-MS/MS).
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Midazolam 8 mg were orally administered to 10 male healthy volunteers before and after GBE intake. - AUC0-alpha for midazolam was singnificantly (25%) increased by GBE intake and oral clearance was significantly (26%) decreased.Note : - Data incomplete
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Midazolam 8 mg were orally administered to 10 male healthy volunteers before and after GBE intake. - AUC0-alpha for midazolam was singnificantly (25%) increased by GBE intake and oral clearance was significantly (26%) decreased.Note : - Data incomplete
Part Used : ใบActivity : CYP3A4 INHIBITIONSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : - Midazolam 8 mg were orally administered to 10 male healthy volunteers before and after GBE intake. - AUC0-alpha for midazolam was singnificantly (25%) increased by GBE intake and oral clearance was significantly (26%) decreased.Note : - Data incomplete
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : The pupose of study was to assess the ability of single midazolam concentrations to predict midazolam AUC in the presence and absence of CYP3A modulation by GBE. Subjects received oral midazolam 8 mg before and after 28 days of GBE administration. The geometric mean raio (90% confidence intervals) of midazolam AUC 0-infinity - GBE / AUC 0-infinity pre - GBE was 0.66 (0.49-0.84) P = .03). Single midazolam concentrations between 2 and 5 hours correctly predicted the reduction in midazolam AUC following GBE exposure, but confidence intervals were generally wide.Note : Data incomplete.
Part Used : ใบActivity : CYP3A INDUCTIONSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : The pupose of study was to assess the ability of single midazolam concentrations to predict midazolam AUC in the presence and absence of CYP3A modulation by GBE. Subjects received oral midazolam 8 mg before and after 28 days of GBE administration. The geometric mean raio (90% confidence intervals) of midazolam AUC 0-infinity - GBE / AUC 0-infinity pre - GBE was 0.66 (0.49-0.84) P = .03). Single midazolam concentrations between 2 and 5 hours correctly predicted the reduction in midazolam AUC following GBE exposure, but confidence intervals were generally wide.Note : Data incomplete.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extract (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : Midazolam*/Versed/DormicumDose/Conc.(drug) : -Result : PositiveRemark : The pupose of study was to assess the ability of single midazolam concentrations to predict midazolam AUC in the presence and absence of CYP3A modulation by GBE. Subjects received oral midazolam 8 mg before and after 28 days of GBE administration. The geometric mean raio (90% confidence intervals) of midazolam AUC 0-infinity - GBE / AUC 0-infinity pre - GBE was 0.66 (0.49-0.84) P = .03). Single midazolam concentrations between 2 and 5 hours correctly predicted the reduction in midazolam AUC following GBE exposure, but confidence intervals were generally wide.Note : Data incomplete.
